Psychedelic Research

Optimi Health Completes First Psilocybin Export to UK for Phase 2 Trial

Optimi Health Completes First Psilocybin Export to UK for Phase 2 Trial

Optimi Health Corp. has exported naturally derived psilocybin to the UK for a planned Phase 2 clinical trial, marking a milestone in international psychedelic drug distribution.

June 10, 2026
Optimi Health Welcomes Australia's TGA Framework Update, Expanding Psychedelic Therapy Access

Optimi Health Welcomes Australia's TGA Framework Update, Expanding Psychedelic Therapy Access

Optimi Health Corp. highlights Australia's updated TGA framework for psilocybin and MDMA, which broadens therapy teams and treatment settings, potentially accelerating adoption of psychedelic-assisted therapy.

May 29, 2026
DEA Advances Psilocybin Rescheduling Petition to HHS for Scientific Review

DEA Advances Psilocybin Rescheduling Petition to HHS for Scientific Review

The DEA's decision to forward psilocybin rescheduling for scientific review marks a significant regulatory shift that could expand medical access for veterans and palliative care patients while accelerating psychedelic research.

August 28, 2025